Advances in Animal Models and Precision Medicine for Cancer Research

Guest Editors:

Dr. James Meehan
The Royal (Dick) School of Veterinary Studies, Roslin Institute, The University of Edinburgh, Edinburgh, Midlothian, Scotland, UK

Dr. Mark E. Gray
The Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, Midlothian, Scotland, UK

Deadline for manuscript submissions:
30 November 2024

Message from the Guest Editors

Treating individual patients based on specific factors, such as biomarkers, is what differentiates precision medicine from standard treatment regimens. The arrival of precision medicine has transformed translational cancer research, suggesting an approach that is patient-focused, with treatment choices directed by prognostic/predictive/monitoring biomarkers. The overall aim of translational research is to produce meaningful results that can quickly benefit cancer patients. Humans are complex organisms; if translational research is to be carried out, the models used should mimic that complexity. Animal models have been vital to cancer research, having been used in studies ranging from the investigation of the mechanisms of cancer development/progression, to studies on cancer drug screening and biomarker research. Major advancements have been made in recent decades on animal cancer models, which have become progressively more complex due to the use of new and improved technologies.

In this Special Issue, we invite authors to submit articles focusing on animal models and how their use can lead to advancements in precision medicine for cancer.

mdpi.com/si/202314

Special Issue

Editor-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.
Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us